EHEsfandiar Heidarian

Esfandiar Heidarian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Esfandiar Heidarian has a total of 99 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluating the efficacy of N-acetyl-cysteine in combination with naloxone for the treatment of patients with methadone poisoning; a double-blind randomized clinical trial

    by Zahra Karimi Taghanaki, Pantea Ramezannezhad, Esfandiar Heidarian, Elham Raeisi

    Introduction: Methadone overdose is a severe and possibly fatal situation. Its routine treatment is naloxone therapy, meanwhile, N-acetylcysteine (NAC) may be effective in its clinical symptom improvement. Objectives: This study aimed to assess the effectiveness of combining NAC with naloxone in treating patients who have overdosed on methadone. Patients and Methods: This double-blind clinical trial was conducted on patients with methadone intoxication referred to Kashani Hospital in Shahrekord, Iran, from May to December 2021. Before the study began, written informed consent was obtained from the patients, and they were randomly assigned to two groups of intervention and control, with 32 patients in each group. In the control group, standard treatment with naloxone was administered, whereas in the intervention group, NAC was added to the standard treatment. The outcome measures included hemodynamic parameters, arterial blood gas analysis, and liver functional tests, which were assessed before and after the intervention, were compared between the two groups using statistical tests. Results: The study results indicated that the mean age of the control and intervention groups was 43.09 and 44.21 years, respectively. Demographic characteristics were similar between the two groups. The comparative analysis of the mean differences in changes in hemodynamic and biochemical parameters between the control and intervention groups revealed that the changes in mean arterial pressure (MAP), respiratory rate (RR), temperature (T), pH, and bicarbonate (HCO3 ) were not statistically significant (P>0.05). Conversely, the mean differences in changes of pulse rate (PR), partial pressure of carbon dioxide (PCO2 ), partial pressure of oxygen (PO2 ), alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP) were found to be statistically significant (P<0.05). This analysis demonstrated significant reductions in PR, PCO2 , and liver function tests (LFTs) including ALT, AST, and ALP in the intervention group compared to the control group. In contrast, the PO2 showed a positive change, with the intervention group exhibiting a greater increase compared to the control group. Conclusion: We conclude that NAC has a positive impact on the treatment of methadone intoxication, especially in improving liver function and respiratory parameters. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (IRCT20210222050462N1, https://irct.behdasht.gov.ir/trial/55313; ethical code from Shahrekord University of Medical Sciences; IR.SKUMS.REC.1399.244).

  • Open Access

    Investigating the effect of adding silymarin to the standard treatment of naloxone in methadone intoxication; a double-blind clinical trial

    by Maryam Hadipoor Chamgarani, Esfandiar Heidarian, Elham Raeisi, Pantea Ramezannezhad

    Introduction: In cases of methadone intoxication, the drug is mainly processed by the liver, however, its elimination through the kidneys is also crucial. On the other hand, naloxone therapy is a gold standard treatment for opioid intoxication, the addition of other drugs can improve its benefits and reduce side effects. Objectives: This study aimed to assess the effectiveness of adding silymarin to the standard treatment of naloxone in patients with methadone intoxication, to improve patient outcomes and reduce the risk of complications associated with alone naloxone therapy. Patients and Methods: This clinical trial study aimed to investigate the efficacy of silymarin in combination with standard treatment for methadone intoxication patients. The study employed a control group, which received standard treatment with naloxone, and an intervention group, which received both naloxone and silymarin. Liver functional tests (LFTs), kidney functional tests, malondialdehyde (MDA), and ferric-reducing ability of plasma (FRAP) were measured at admission and post-intervention times to compare the outcomes between the two groups. Statistical analyses, including chi-square, independent and paired t tests, Wilcoxon, and Mann-Whitney tests were conducted to identify significant differences between the groups. Results: Results indicated that 32 and 33 patients were included in the naloxone and naloxone + silymarin groups, respectively. The results showed that the changes in kidney functional tests such as blood urea nitrogen (BUN) and creatinine (Cr), MDA, and FRAP were not statistically significant between the two groups. However, the changes in LFTs, including, aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP), were statistically significant. Notably, the LFT changes were more pronounced in the group receiving both naloxone and silymarin, indicating a greater reduction in liver enzymes in this combined treatment group. Conclusion: The addition of silymarin to standard naloxone treatment for methadone intoxication patients could improve liver function, as the combined therapy showed a more pronounced reduction in liver enzyme levels compared to standard treatment alone; however, this combination treatment could not change the kidney function and oxidative stress markers. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT20210216050377N1; ethical code from Shahrekord University of Medical Sciences; IR.SKUMS.REC.1400.048). This study was also registered in Research Registry website with Unique Identifying Number (UIN) of researchregistry10395.

  • Open Access

    Comparative evaluation of the serum biochemical and lipid profile changes in spayed male and female rats

    by Abdolrasoul Namjou, Esfandiar Heidarian, Abuzar Alikhani

    Background and aims: This study investigated the effects of gonadal removal in male and female rats on changes in serum biochemical parameters. Methods: Twenty-eight adult male and female rats were divided into four groups of 7 animals for a period of 9 weeks. The first and second groups of intact male and female rats, as well as the third and fourth groups of male and female rats, were gonadectomized, respectively. At the end of the ninth week of the study, the rats were anesthetized with chloroform, and the amount of glucose, some lipid parameters in serum, and the activity of a number of serum enzymes were measured after taking blood from the heart. Results: Alanine aminotransferase, and alkaline phosphatase (ALP) levels were higher in intact male rats than in intact female rats, respectively (P=0.03, P=0.015). The amounts of glucose and cholesterol of low-density lipoprotein (LDL) in intact female rats were higher than in the ovariectomized rats, respectively (P=0.07, P=0.039, P=0.03). The amount of lactate dehydrogenase (LDH) in spayed female rats demonstrated a significant increase compared to other groups (P=0.001). However, there was a significant decrease in calcium levels in gonadectomized rat groups in comparison to intact female rats (P=0.02). Finally, a significant increase was found in phosphorous levels in the intact male rats group compared to other groups (P=0.002). Conclusion: Decreased sex hormones in gonadectomized rats compared with intact rats could lead to increased serum levels of LDH, ALP, and LDL cholesterol that may result in the development of metabolic and atherogenesis syndromes and acute liver failure.

  • Open Access

    Effects of Hirudotherapy in Alloxan-induced Diabetic Male Rats: Histopathological and Biochemical Changes

    by Abdolrasoul Namjou, Ebrahim Razavie, Esfandiar Heidarian, Nasser Yazdani, Mahmoud Rafieian-Kopaei

    Background: Hirudotherapy is very common in traditional Iranian medicine for treating various diseases, including hyperglycemia. However, there is no scientific research to evaluate its effect on diabetes mellitus and the possible side effects. Objectives: This study aimed to evaluate the biochemical and histopathological changes in healthy and diabetic male rats treated with leeches. Methods: This experimental study was performed on 28 male Albino Wistar rats randomly divided into control, diabetic, and two treatment groups (control and diabetic rats treated with Hirudo medicinalis). Hirudotherapy was done in 3 to 5 minutes every 5 days for 28 consecutive days. At the end of the study, blood glucose, biochemical activity of the liver, kidney, and serum lipid enzymes were evaluated by enzymatic methods. Pathological changes in liver, kidney, and pancreas tissues were studied in the experimental groups. Results: The levels of blood glucose, aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), creatinine (Cr), urea, and phosphorus significantly increased in diabetic rats treated with leeches compared to the control group (P

  • Role of NF‐κB/IL‐1β Pathway and Caspase 3 in Mediating the Hepatoprotective Effect of Rutin against Paraquat‐Induced Liver Toxicity in Male Rats

    by Sahar Rafiee, Ali Nouri, Esfandiar Heidarian

    One of the most common bipyridinium herbicides that can lead to liver toxicity is paraquat. Rutin is a bioflavonoid with antioxidant, anti‐inflammatory, anti‐hepatotoxic, and antimicrobial properties. The effect of rutin on paraquat‐induced liver toxicity was examined in this study. 48 male rats were divided into six groups: the control group was given a normal diet; the non‐treated group was given paraquat; the positive control group was given paraquat, and silymarin and the treatment groups were given paraquat and rutin at doses of 25, 50, and 100 mg/kg. After fourteen days, the rats were anesthetized by xylazine‐ketamine, and fasting blood samples were obtained from their hearts to measure alkaline phosphatase (ALP), aspartate transaminase (AST), alanine transaminase (ALT), malondialdehyde (MDA), creatinine, lipid profile, antioxidant capacity, and carbonyl protein. The liver tissue was removed to measure the levels of catalase (CAT), superoxide dismutase (SOD), total protein, vitamin C, plus NF‐κB, IL1β, and caspase‐3 gene expressions. Paraquat gavage in the untreated group (group 2) for 14 days in comparison with the control group induced a significant augmentation (p<0.05) in levels of lipid profile, AST, ALP, ALT, MDA, carbonyl protein, and also NF‐κB, IL1β, Caspase3 expressions. Treatment with rutin reduced the factors as mentioned above. Paraquat poisoning induced a substantial decline (p<0.05) in HDL content, FRAP level, CAT, and SOD activity of the liver compared to the control group. However, rutin oral treatment led to a substantial increase (p<0.05) in the level of these factors compared to the paraquat‐only treated group. Based on the findings of the present study, it was found that rutin can be significantly effective in improving hepatotoxicity caused by paraquat.


  • Open Access

    Moving toward being internationally scooped

    by Esfandiar Heidarian, Elham Raeisi

    Moving toward being internationally scooped

  • Ferulic acid prevents cyclosporine-induced nephrotoxicity in rats through exerting anti-oxidant and anti-inflammatory effects via activation of Nrf2/HO-1 signaling and suppression of NF-κB/TNF-α axis

    by Ali Nouri, Keihan Ghatreh-Samani, Hossein Amini-Khoei, Asghar Mohammadi, Esfandiar Heidarian, Mohammad Najafi

    Cyclosporine is one of the main immunosuppressive agents used in the treatment of autoimmune diseases or transplantation. Despite the favorable effects, cyclosporine-mediated nephrotoxicity critically restricts the clinical use of the agent. Given this, herein, we aimed to evaluate whether ferulic acid could prevent cyclosporine-mediated nephrotoxicity in rats. A total of 32 Wistar rats were chosen to be treated with cyclosporine, ferulic acid, and the combination of both agents for 21 days. To evaluate the nephron-protective mechanism of ferulic acid, the serum levels of biochemical parameters, as well as the tissue levels of several oxidative and anti-oxidative mediators, were examined. The expression and the tissue levels of nuclear factor (NF)-κB, tumor necrosis factor (TNF)-α, heme oxygenase (HO-1), and nuclear factor erythroid 2-related factor 2 (Nrf2) were evaluated using the qRT-PCR and ELISA, respectively. Our results showed while cyclosporine elevated the serum levels of renal-related markers in the rats, in the presence of ferulic acid, there was a significant reduction in the levels of urea, uric acid, creatinine, and sGOT. Moreover, we found that ferulic acid remarkably prevented cyclosporine-mediated nephrotoxicity by restoring the anti-oxidant system through activating the Nrf2/HO-1 axis. By halting the NF-κB-mediated upregulation of TNF-α, it also seems that ferulic acid prevented lymphocytes infiltration into kidney tissue and consequently suppressed inflammatory responses. Overall, the results of the present study suggest that due to the anti-oxidant and anti-inflammatory properties of ferulic acid, this agent could be used alongside cyclosporine to reduce its adverse effects on kidney tissue.


  • Open Access

    Protective effect of carvacrol against hepato-renal toxicity induced by azathioprine in rats

    by Fariba Houshmand, Esfandiar Heidarian, Amine Shirani Faradonbeh, Somayyeh Najafi Chaleshtori

    Background and aims: Azathioprine (AZA) is an immunosuppressant medication that has toxicity to kidneys and liver. This study aimed to investigate the protective activity of carvacrol (CAR) against hepatorenal toxic activity of AZA in male Wistar rats. Methods: All study rats were divided into five groups: control (saline, ip); azathioprine-only (AZA 50 mg/kg, ip), Sily+AZA (Silymarin 50 mg/kg, gavage), CAR+AZA (CAR 10 mg/kg, gavage), and CAR+AZA (CAR 20 mg/kg, gavage) groups. Silymarin was used as the standard hepatoprotective drug. The drugs were administered once daily for 21 days in III-V groups, and a single dose of AZA was injected on the seventh day of the experiment. Results: AZA-intoxicated rats exhibited an elevation in aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP) activity in serum, as well as an increase in extent of lipid peroxidation. Activities of enzymatic antioxidants (superoxide dismutase – SOD, catalase - CAT) in the serum, liver, and kidney were decreased as for the AZA group (P<0.05). Co-treatment of CAR (both doses of 10 and 20 mg/kg) lowered the serum transaminases and ALP level, the elevation of endogenous enzymes levels, and the malondialdehyde (MDA) in serum and both tissues (P<0.05). This protective effect was greater in CAR 10 compared to 20 mg/kg doses, which was comparable to silymarin. Conclusion: This study demonstrated that the renal and nephrotoxic activities of AZA could be attributed to the generated increased oxidative stress, as well as to the CAR with antioxidant effect similar to that in silymarin, which protected these tissues against AZA-induced nephrotoxicity hepatotoxicity.